# Does Science Support Senolytics or Antioxidants for Aging

Science overwhelmingly demonstrates that daily antioxidant supplements fail to slow human aging and can actively interfere with the body's vital cellular repair mechanisms. In contrast, emerging clinical evidence supports senolytics—intermittent therapies that actively hunt and destroy toxic, aged cells—as a more promising, albeit highly experimental, strategy for reversing tissue dysfunction and extending human healthspan. 

## The Promise and Failure of the Antioxidant Paradigm

For decades, the global anti-aging industry has been heavily anchored to the free radical theory of aging. Conceived in the 1950s by Denham Harman, this theory provided a neat, intuitive explanation for why our bodies deteriorate over time [cite: 1, 2, 3]. The premise relies on the fundamental mechanics of cellular respiration. When our mitochondria convert oxygen and nutrients into adenosine triphosphate (ATP) for energy, they inevitably produce highly unstable metabolic byproducts known as reactive oxygen species, or free radicals [cite: 2, 3, 4]. 

Because these molecules contain an unpaired electron, they aggressively seek out other molecules to steal electrons from, causing oxidative damage to cell membranes, proteins, and even nuclear and mitochondrial DNA [cite: 2, 3, 5]. Over years and decades, this cumulative oxidative stress was believed to be the primary engine driving senescence, tissue degradation, and the onset of age-related conditions like cardiovascular disease, Alzheimer's, and cancer [cite: 2, 3, 5, 6].

The logical countermeasure birthed a multi-billion-dollar wellness industry: antioxidants. Antioxidants are molecules—either produced naturally by the body or consumed through diet and supplements—that can safely donate an electron to a free radical without becoming unstable themselves [cite: 2]. The prevailing public assumption became that flooding the body with exogenous antioxidants, such as high-dose vitamin C, vitamin E, and beta-carotene, would neutralize the biological wear and tear of aging [cite: 1, 7]. Today, the global anti-aging supplement market continues to expand rapidly, projected to reach nearly ten billion dollars over the next decade [cite: 8, 9].

### Why Antioxidant Supplements Falter in Humans

Despite their popularity, the scientific consensus regarding antioxidant supplements has shifted dramatically. While antioxidants reliably quench free radicals in a test tube, human biology is far less accommodating. The vast majority of over-the-counter antioxidant supplements suffer from incredibly poor bioavailability. They are difficult for the human digestive tract to absorb, are often chemically transformed in the liver, and are rapidly eliminated before they can effectively reach target cells in meaningful concentrations [cite: 10].

More critically, rigorous epidemiological data has delivered a severe blow to the idea that antioxidant supplementation extends human lifespan. A sweeping meta-analysis analyzing mortality data from randomized controlled trials involving over two hundred thousand initially healthy subjects found no evidence that supplemental antioxidants improve survival [cite: 7, 11]. The data proved even more alarming: the analysis convincingly demonstrated that high-dose supplementation with specific antioxidants, including beta-carotene, vitamin A, and vitamin E, may actually increase all-cause mortality compared to placebo [cite: 7, 11]. 

Furthermore, evidence suggests that excessive antioxidant intake can be specifically harmful in patients with active malignancies, as an overabundance of antioxidants can inadvertently protect cancer cells from the oxidative stress that would otherwise destroy them, potentially accelerating tumor growth [cite: 1]. Acknowledging this mounting evidence, institutions like the United States Department of Agriculture went so far as to remove their database of antioxidant food values, citing that the numbers had no direct relevance to human health outcomes and were routinely misused by supplement manufacturers to market ineffective products [cite: 10].

### The Hormesis Paradox and Exercise Interference

The most glaring flaw in the free radical theory of aging is its failure to account for the concept of mitohormesis. Hormesis is a biological phenomenon wherein exposure to a mild, transient stressor triggers an adaptive response that leaves the organism stronger and more resilient to future stress [cite: 1, 2]. 

Reactive oxygen species are not universally destructive rogue elements; they play an indispensable role as intracellular signaling molecules. When you engage in physical exercise, your muscle cells demand massive amounts of energy, causing your mitochondria to produce a localized surge of free radicals [cite: 4, 12, 13]. Rather than causing permanent damage, this acute oxidative stress activates critical signaling pathways. Molecules like hydrogen peroxide act as messengers, signaling to kinases and transcription factors—such as AMPK, p38 MAPK, and the Keap1-Nrf2 pathway—that the muscle is under strain [cite: 4, 12, 14]. 

These signals prompt the cell to adapt by building new, highly efficient mitochondria and massively upregulating the body's own endogenous antioxidant defense systems, such as superoxide dismutase, catalase, and glutathione peroxidase [cite: 13, 14, 15]. This intrinsic response is far more powerful than any pill. 

However, when athletes or aging adults consume high doses of exogenous antioxidant supplements immediately before or after a workout, they artificially neutralize these free radicals before the signaling cascade can occur [cite: 12, 13]. By muting the oxidative signal, the supplements effectively blind the cells to the stress of exercise. Extensive research demonstrates that this practice can blunt or entirely prevent the beneficial adaptations of physical training, including improvements in insulin sensitivity, vascular function, and muscle hypertrophy [cite: 12, 14, 16]. In short, the attempt to aggressively maintain cellular perfection with antioxidants actually prevents the body from fortifying itself.

## The Biology of Cellular Senescence

With the limitations of the antioxidant paradigm clearly established, the field of geroscience shifted its focus toward a much more fundamental root cause of aging and chronic disease: cellular senescence. 

The concept was first documented in 1961 by scientists Leonard Hayflick and Paul Moorhead, who observed that normal human somatic cells grown in a laboratory do not divide infinitely [cite: 17, 18, 19]. After a certain number of population doublings—now known as the Hayflick limit—the cells cease replication entirely [cite: 18, 19]. We now understand that this replicative senescence is primarily driven by telomere attrition. With each cell division, the protective caps at the ends of our chromosomes shorten. Once they become critically short, the cell triggers a permanent arrest of the cell cycle to prevent the replication of corrupted genetic material [cite: 15, 18, 20].

However, telomere shortening is not the only trigger. Cells can be forced into premature senescence by a variety of severe intrinsic and extrinsic stressors. These include irreparable DNA double-strand breaks, severe oxidative stress, oncogene activation, radiation exposure, and profound mitochondrial dysfunction [cite: 15, 18, 19]. 

### How a Healthy Cell Becomes a Zombie

When a cell detects critical damage, it faces a biological crossroads. If the damage is overwhelming, the cell may trigger apoptosis, a clean, highly regulated form of programmed cell death where the cell is dismantled and its components are recycled by the immune system [cite: 3, 21]. Alternatively, the cell may activate tumor suppressor pathways, primarily the p53/p21CIP1 and p16INK4A/pRB networks, locking the cell into a state of essentially irreversible growth arrest [cite: 18, 19, 22]. 

In a young, healthy organism, this senescence program is a highly beneficial, evolutionarily conserved defense mechanism. It is a potent anti-cancer safeguard, ensuring that mutated or severely damaged cells cannot proliferate and form tumors [cite: 18, 19, 22]. Furthermore, transient senescence plays vital physiological roles during embryonic development and tissue repair. For example, during wound healing, senescent cells help coordinate the initial stages of tissue remodeling before being efficiently cleared away by a robust immune system [cite: 22, 23].

The problem arises chronologically. As we age, the rate at which we generate damaged cells increases, while our immune system's ability to locate and eliminate these cells simultaneously declines—a phenomenon known as immunosenescence [cite: 17, 20]. Consequently, these non-dividing, damaged cells begin to accumulate in our skin, blood vessels, adipose tissue, joints, and brain [cite: 17, 24].

### The Senescence-Associated Secretory Phenotype (SASP)

Senescent cells are frequently referred to as "zombie cells" in popular media because they refuse to undergo normal cell death, yet they are far from biologically inactive. Once a cell enters a persistent senescent state, it undergoes dramatic metabolic reprogramming and begins to express what is known as the Senescence-Associated Secretory Phenotype, or SASP [cite: 18, 19, 22].

The SASP is a complex, toxic localized environment. The zombie cell continuously secretes a potent cocktail of pro-inflammatory cytokines (such as Interleukin-6 and Interleukin-1-beta), chemokines, growth factors, and tissue-degrading matrix metalloproteinases [cite: 15, 18, 22]. Originally, the evolutionary purpose of this secretion was to act as an emergency flare, signaling the immune system to come and clear the damaged cell while temporarily halting the growth of nearby healthy cells [cite: 15, 22]. 

However, when senescent cells persist for months or years, their continuous SASP secretions wreak havoc on surrounding tissue architecture. This chronic, sterile, low-grade inflammation is termed "inflammaging," and it is widely considered a root driver of tissue degeneration [cite: 17, 20]. The SASP degrades the extracellular matrix, impairs the function of local adult stem cells, and can even induce neighboring, perfectly healthy cells to become senescent in a destructive paracrine cascade [cite: 17, 22, 25].

Preclinical studies underscore just how destructive these cells can be. Researchers have demonstrated that injecting a vanishingly small number of senescent cells—as few as one in ten thousand—into the knee joints or abdominal cavities of young, healthy mice is sufficient to induce physical frailty, osteoarthritis-like symptoms, and significantly shorten their natural lifespan [cite: 24, 26]. Conversely, researchers theorized that if they could safely remove these accumulating zombie cells, they might fundamentally delay or alleviate multiple age-related disorders simultaneously [cite: 17, 18, 24].



## Senolytics: The Demolition Strategy for Longevity

The realization that senescent cells act as active drivers of age-related pathology birthed a completely new therapeutic paradigm. In 2015, researchers at the Mayo Clinic, led by Dr. James Kirkland and Dr. Tamar Tchkonia, coined the term "senolytics"—a portmanteau of senescence and lytic (destroying) [cite: 17, 24, 25]. Unlike antioxidants, which attempt to maintain and protect existing cellular machinery, senolytics are demolition agents designed to selectively hunt and kill senescent cells without harming healthy tissue [cite: 21, 25, 27].

[image delta #1, 0 bytes]



The central challenge of developing a senolytic is selectivity. How do you kill a senescent cell while sparing the healthy cells surrounding it? The answer lies in the zombie cell's own defense mechanisms. 

### Exploiting Anti-Apoptotic Pathways (SCAPs)

Because senescent cells are constantly generating an incredibly toxic, pro-inflammatory internal environment, they should theoretically self-destruct [cite: 25]. To survive their own toxicity, senescent cells uniquely upregulate a series of pro-survival networks known as Senescent Cell Anti-Apoptotic Pathways, or SCAPs [cite: 21, 28]. These molecular shields—which include the BCL-2 protein family, PI3K/Akt pathways, and specific tyrosine kinases—prevent the cell from undergoing programmed apoptosis [cite: 15, 21, 29]. 

Senolytic agents exploit this specific biological vulnerability. By deploying drugs that temporarily disable these SCAP networks, the senescent cell's biological shields drop. Unable to withstand its own toxic environment, the senescent cell rapidly undergoes apoptosis [cite: 21, 28, 30]. Healthy cells, which do not rely on these hyper-activated survival pathways, remain largely unaffected by the brief chemical intervention [cite: 21, 28].

### The Crucial Hit-and-Run Dosing Protocol

Perhaps the most radical departure from traditional pharmacological treatments and nutritional supplementation is how senolytics are administered. Chronic diseases like hypertension or hypercholesterolemia generally require continuous, daily medication. Antioxidant supplements are similarly consumed every single morning. Senolytics, however, are administered using an intermittent, "hit-and-run" protocol [cite: 25, 31, 32].

The biological rationale for this is straightforward. It takes a damaged cell roughly two to six weeks to fully enter a senescent state and develop the tissue-damaging SASP profile [cite: 29, 33, 34]. Therefore, there is no need to keep senolytic drugs continuously circulating in the bloodstream. In clinical trials, patients typically consume high doses of senolytics for just two or three consecutive days, followed by a prolonged treatment-free window of several weeks or even months [cite: 35, 36]. 

This hit-and-run approach offers immense clinical advantages. First, the goal is not to achieve a steady-state blood concentration, but rather to trigger the apoptotic cascade; once the suicide sequence is initiated in the zombie cell, the drug's job is done and it can be rapidly cleared from the body [cite: 32, 37]. Second, minimizing the patient's exposure time to these highly potent compounds drastically mitigates the risk of severe side effects, off-target toxicity, and immune suppression [cite: 31, 32, 35]. 

### When Antioxidants Become Targeted Toxins

A fascinating nuance in senotherapeutics is that some of the most promising natural senolytic compounds—like quercetin and fisetin—are actually classified as flavonoids and dietary antioxidants [cite: 19, 28, 36]. This begs the question: how does an antioxidant kill a cell?

The answer lies in the unique metabolic state of the senescent cell, combined with the massive doses utilized in senolytic protocols. While these compounds may act as gentle free radical scavengers at standard dietary levels, they exhibit powerful prooxidant activities when administered in heavy, concentrated bursts [cite: 30]. Senescent cells tend to accumulate high intracellular levels of transition metals, particularly iron and copper. When high-dose flavonoids interact with these metals inside the zombie cell, the reaction amplifies the prooxidant effect, generating massive oxidative damage that overloads the senescent cell's defenses and kills it [cite: 30]. 

Thus, in the context of senolytic therapy, these compounds are not functioning to buffer age-related wear and tear; they are being weaponized to target the unique metabolic vulnerabilities of aged cells.

### Strategy Comparison Summary

| Feature | The Antioxidant Paradigm | The Senolytic Paradigm | The Senomorphic Paradigm |
| :--- | :--- | :--- | :--- |
| **Primary Mechanism** | Neutralizes reactive oxygen species (ROS) to prevent molecular oxidation and DNA damage. | Disables anti-apoptotic pathways (SCAPs) to induce death in senescent cells. | Modulates cellular pathways to suppress the inflammatory SASP without killing the cell. |
| **Dosing Schedule** | Continuous, daily nutritional supplementation. | Intermittent "hit-and-run" (e.g., 2 days on, weeks/months off). | Chronic or sustained administration, similar to traditional disease management. |
| **Impact on Signaling** | Can inadvertently blunt vital physiological adaptations, such as exercise-induced mitochondrial growth. | Halts pathological signaling permanently by removing the cells generating the SASP. | Reversibly suppresses pathological signaling; inflammation may return if the drug is stopped. |
| **Clinical Efficacy** | Failed to extend lifespan in rigorous human trials; high doses may increase all-cause mortality. | Shown to extend healthspan in mice; early human trials show reduced senescent burden and functional benefits. | Strong preclinical data for alleviating fibrosis and neurodegeneration; early human trials ongoing. |
| **Current Safety Profile** | Generally safe at dietary levels, but high-dose isolates suffer from poor bioavailability and toxicity risks. | Investigational. Carries risks of cytopenia and off-target cell death depending on the pharmaceutical agent used. | Investigational. Carries risks of broad immune suppression due to sustained pathway inhibition. |

## Leading Senolytic Agents in Clinical Development

The field of senotherapeutics is highly diverse, utilizing everything from repurposed chemotherapy agents to synthetic peptides and concentrated plant extracts. Because senescent cells are highly heterogeneous—meaning a senescent fat cell utilizes different survival mechanisms than a senescent brain cell—no single drug clears all zombie cells throughout the body [cite: 25, 38]. Consequently, researchers frequently combine agents.

### Dasatinib and Quercetin (D+Q)

The most extensively documented and rigorously tested senolytic regimen to date is the combination of Dasatinib and Quercetin (D+Q) [cite: 28, 39, 40]. Dasatinib is an FDA-approved tyrosine kinase inhibitor originally developed as a targeted chemotherapy for chronic myeloid leukemia [cite: 35, 41]. Quercetin is a naturally occurring plant polyphenol found in apples, onions, and capers [cite: 19, 36, 39].

The rationale for the combination is purely synergistic. In preclinical screening, researchers discovered that Dasatinib is highly effective at inducing apoptosis in senescent human preadipocytes (fat cells) and endothelial cells, while Quercetin more efficiently targets senescent human endothelial cells and bone marrow-derived mesenchymal stem cells [cite: 28, 42]. By combining them, researchers cast a wider biological net, successfully clearing a broader range of tissue-damaging cells.

In animal models, the D+Q cocktail has demonstrated staggering results, delaying or alleviating over 40 age-related conditions, including osteoporosis, insulin resistance, vasomotor dysfunction, liver steatosis, and neurodegeneration, while extending the healthspan of naturally aged mice [cite: 29, 30, 40]. 

However, Dasatinib is a highly potent pharmaceutical with a non-trivial risk profile. When used continuously in oncology, it carries severe hematologic toxicity risks, including life-threatening neutropenia and thrombocytopenia (dangerously low platelet counts), as well as pleural effusion (fluid around the lungs) [cite: 21, 30, 35]. Dasatinib is also a CYP3A4 substrate, meaning it interacts dangerously with common medications like erythromycin and certain antifungals [cite: 30]. While the hit-and-run dosing schedule minimizes these dangers, D+Q remains an aggressive experimental intervention, not a consumer wellness supplement [cite: 31, 32, 35].

### Fisetin: The Strawberry Flavonoid

Driven by the need for safer, lower-toxicity alternatives, researchers expanded their screening of natural compounds. Fisetin, a flavonoid structurally similar to quercetin and found naturally in strawberries and cucumbers, quickly emerged as a frontrunner [cite: 19, 28, 38]. 

In a comprehensive panel testing ten different flavonoids in mice suffering from accelerated aging (progeria), fisetin proved to be the most potent senolytic monotherapy, successfully reducing the accumulation of p16 and p21-positive senescent cells in adipose tissue, the spleen, liver, and kidneys [cite: 36, 42]. Remarkably, even when administered to mice very late in life—roughly equivalent to a human starting treatment at age 60 or 70—fisetin preserved grip strength, reduced systemic inflammation, and extended their remaining lifespan [cite: 29, 38].

Fisetin's appeal lies in its dual action and safety profile. It acts as both a senolytic (killing cells by exploiting prooxidant vulnerability) and a potent senomorphic (inhibiting the mTOR pathway to slow the rate at which healthy cells become senescent) [cite: 25, 28, 38]. It lacks the severe hematologic risks associated with chemotherapy drugs, making it an attractive candidate for human clinical translation [cite: 37, 38]. 

It is vital to note that dietary consumption of strawberries cannot replicate these effects. To achieve the necessary pharmacokinetic threshold for senolysis in humans, clinical trials utilize massive oral doses of highly bioavailable fisetin extract (typically 20 mg/kg/day)—a concentration equivalent to consuming 15 pounds of raw strawberries in a matter of minutes [cite: 34, 43].

### BCL-2 Inhibitors and Navitoclax

Beyond D+Q and fisetin, synthetic molecules designed to inhibit specific anti-apoptotic proteins are moving through the pipeline. Navitoclax (ABT-263), a potent inhibitor of the BCL-2 family of survival proteins, has shown high efficacy in clearing senescent cells in varied tissues in mice [cite: 21, 28, 44]. However, its clinical development as a systemic anti-aging drug has been severely hampered by dose-limiting toxicity. Because platelets heavily rely on the BCL-xL protein for survival, Navitoclax causes immediate and profound thrombocytopenia, rendering it too dangerous for broad prophylactic use in otherwise healthy older adults [cite: 21, 38]. Consequently, companies are exploring localized delivery systems for these potent synthetics, such as injecting them directly into arthritic joints or the eye [cite: 31, 45].

## Human Clinical Trials: What the Data Shows So Far

The transition from extending the healthspan of mice to treating chronic human disease is currently unfolding across dozens of registered clinical trials worldwide [cite: 26, 46]. Because it is difficult to gain regulatory approval to treat "aging" as a disease, the first wave of human senolytic trials is explicitly targeting severe, localized conditions driven by cellular senescence [cite: 29, 47].

### Idiopathic Pulmonary Fibrosis and Kidney Disease

The very first proof-of-concept human trials for senolytics targeted idiopathic pulmonary fibrosis (IPF)—a fatal, progressive scarring of the lungs where senescent cells are known to aggregate and drive fibrotic tissue remodeling [cite: 29, 45, 47]. In a pilot study, patients with IPF received nine intermittent doses of D+Q over three weeks. The results demonstrated the first evidence of functional improvement in humans, with patients exhibiting measurable increases in their six-minute walk distance, walking speed, and chair-rise ability—improvements rarely seen in a disease characterized by relentless decline [cite: 47, 48]. 

Subsequent phase 2 trials at the Mayo Clinic evaluated D+Q in patients suffering from diabetic chronic kidney disease. Following a brief three-day treatment regimen, researchers biopsied the patients' adipose tissue and drew blood. The data proved critical: the short burst of D+Q successfully reduced the total burden of senescent cells in the fat tissue and significantly decreased the levels of circulating inflammatory SASP factors in the bloodstream [cite: 30, 38, 49]. This confirmed that senolytics successfully engage their biological targets in living humans.

### Alzheimer’s Disease: The SToMP-AD Trial

Given the devastating lack of curative treatments for neurodegeneration, the potential for senolytics to treat Alzheimer's disease is generating massive scientific interest. Preclinical models established that cellular senescence is mechanistically linked to the accumulation of toxic tau proteins and amyloid-beta plaques in the brain [cite: 50, 51, 52]. 

The SToMP-AD phase 1 clinical trial, conducted by the University of Texas Health Science Center, was the vanguard study testing senolytics in the human brain. Five patients (aged 70 to 82) with early-stage symptomatic Alzheimer's disease were administered intermittent D+Q over 12 weeks [cite: 50, 53, 54]. 

The primary goal of the trial was safety and to determine if the drugs could cross the highly selective blood-brain barrier. The trial succeeded on both fronts: dasatinib was clearly detected in the cerebrospinal fluid (CSF) of the participants, and the regimen was well-tolerated with no severe adverse events or early discontinuations [cite: 50, 51, 52]. Biomarker analysis revealed significant increases in IL-6 and GFAP levels in the CSF immediately post-treatment, coupled with decreases in other senescence-related chemokines [cite: 51, 52]. Researchers hypothesize that this transient spike in specific inflammatory markers indicates target engagement—the senescent astrocytes in the brain were actively dying and bursting open, releasing their internal contents [cite: 55]. 

However, the trial was explicitly designed for safety, not efficacy. As expected in a 12-week study involving advanced neurodegeneration, the patients exhibited no statistically significant improvements in cognitive testing or structural neuroimaging [cite: 50, 52, 53]. While the trial paves the way for larger placebo-controlled studies, it underscores that clearing out cellular debris may not immediately repair complex neurological damage.

### Diabetic Macular Edema and Vision Restoration

One of the most encouraging clinical readouts to date comes from targeted, localized senotherapy. In 2024, Unity Biotechnology reported phase I and IIa trial results for UBX1325, a potent BCL-xL inhibitor designed to treat diabetic macular edema by clearing senescent blood vessels in the retina [cite: 24, 45, 56]. 

Rather than risking systemic toxicity by administering the BCL-xL inhibitor orally, the drug was injected directly into the eye. A single injection led to significant clinical improvements: 62.5% of treated patients gained at least five letters on a vision chart, and 50% gained ten or more letters, effectively halting and partially reversing the progression of vision loss without dose-limiting toxicity [cite: 45, 56]. 

### The Epigenetic Clock Twist

A fascinating 2024 longitudinal study highlighted a complex biological nuance regarding systemic senolytic administration. Researchers sought to determine if clearing senescent cells would rewind a patient's biological age, as measured by DNA methylation "epigenetic clocks" [cite: 57, 58]. 

Nineteen healthy participants underwent a six-month intermittent regimen of D+Q. Surprisingly, the D+Q treatment resulted in statistically significant increases in epigenetic age acceleration and a notable decrease in telomere length [cite: 48, 57, 58]. Researchers theorize that while D+Q efficiently clears out toxic cells, the body must subsequently engage in rapid cellular division to replace the dead tissue. This sudden wave of cellular replication may temporarily shorten telomeres and stress the body's epigenetic markers [cite: 57, 58]. 

However, the study provided a crucial secondary finding. When researchers initiated a subsequent trial adding Fisetin to the D+Q regimen (creating a D+Q+F cocktail), the epigenetic age acceleration was heavily mitigated, resulting in statistically non-significant changes [cite: 48, 57, 58]. Because fisetin possesses both senolytic and broad senomorphic (inflammation-modulating) properties, it appears to cushion the biological stress of cell clearance, underscoring the potential necessity of combination therapies that address both cell death and tissue recovery [cite: 36, 57, 58].

## Senomorphics: Silencing Without Killing

While the demolition approach of senolytics is highly appealing, the potential for off-target toxicity and tissue regeneration imbalances has led many researchers to pursue a parallel strategy: senomorphics [cite: 21, 31, 33]. 

Rather than inducing apoptosis, senomorphic agents are designed to modulate the genetic and metabolic pathways within the senescent cell, effectively silencing the destructive SASP without actually killing the cell [cite: 15, 21, 31]. Because they do not force the body to continuously clear and replace dead tissue, senomorphics may offer a safer route for chronic, long-term administration in older, frail adults [cite: 21, 33]. 

### Rapamycin and Repurposed Therapeutics

Many of the most promising senomorphics are drugs already approved for other conditions. Rapamycin, a potent immunosuppressant used in organ transplants, is the gold standard gerostatic compound [cite: 25, 28]. It works by inhibiting the mTOR signaling pathway, which is a master regulator of cell growth and metabolism [cite: 25, 28]. By dampening mTOR, rapamycin effectively slows the rate at which healthy cells convert into senescent cells and suppresses the secretion of inflammatory cytokines from cells that are already senescent [cite: 25, 28, 31]. While rapamycin drastically extends lifespan in mice, it must be administered carefully in humans to avoid broad immune suppression [cite: 25, 32, 33].

Other common pharmaceuticals are exhibiting surprising senomorphic capabilities. JAK inhibitors, such as ruxolitinib, have shown profound efficacy in suppressing the inflammatory components of the SASP in mouse models of frailty, offering a way to calm systemic inflammation while preserving the beneficial, early-stage functions of senescence [cite: 21, 28, 31]. In a recent randomized controlled trial involving type 2 diabetics, the administration of lipophilic statins (rosuvastatin combined with ezetimibe) successfully reduced the burden of senescent immune cells and lowered systemic inflammation, independent of their cholesterol-lowering effects [cite: 45].

## Global Frontiers in Senotherapy

The pursuit of human longevity is rapidly accelerating, shifting from basic molecular screening toward highly advanced biotechnology and shifting geographically toward heavily funded initiatives in Asia [cite: 44, 46, 59].

### The Senolytic Vaccine Breakthrough in Japan

While small molecule drugs dominate current clinical trials, the future of senolytics may lie in precision immunotherapy. In a landmark 2021 study, researchers at Juntendo University in Japan sought to identify specific protein markers that exist on the surface of senescent cells but not on healthy cells [cite: 60, 61]. Using transcriptome analysis, they discovered that a protein called GPNMB is highly expressed on the surface of senescent vascular cells [cite: 61]. 

Armed with this biological target, the team engineered a peptide vaccine designed to train the mouse's own immune system to hunt and destroy any cell displaying the GPNMB antigen [cite: 61]. The results were staggering: the senolytic vaccine successfully eliminated GPNMB-expressing cells, significantly improved metabolic function and arterial stiffness in mice fed high-fat diets, and measurably extended the lifespan of progeroid mice suffering from accelerated aging [cite: 61]. This research provides a proof-of-concept that we may eventually be able to inoculate patients against the cellular drivers of aging using individualized seno-antigen therapies.

### Systemic Spread and Tissue Lineage Discoveries

Recent breakthroughs out of South Korea and China are fundamentally altering our understanding of how aging cascades through the body. 

In 2025, a research team at Korea University discovered how cellular aging spreads systemically through the bloodstream. They identified a specific, redox-sensitive SASP factor called ReHMGB1 that is secreted by senescent cells, travels through the circulatory system, and robustly induces senescence in remote, previously healthy tissues [cite: 62]. When researchers administered anti-HMGB1 antibodies to middle-aged mice suffering from muscle injury, the treatment halted this systemic spread, allowing the muscle to regenerate and significantly improving the animals' physical performance [cite: 62]. 

Simultaneously, researchers in China—which has recently eclipsed Europe in the volume of initiated clinical trials—developed a highly advanced genetic tracking system known as Sn-cTracer [cite: 59, 63, 64]. This system allowed researchers to selectively track and eliminate senescent cells based on their specific cellular lineage. The study revealed a critical nuance: while removing most senescent cells is beneficial, selectively destroying senescent endothelial cells in the liver actually triggered an accumulation of fibroblasts and dramatically worsened liver fibrosis [cite: 63]. This highlights the absolute necessity of precision medicine in longevity therapeutics; the blind, systemic removal of all senescent cells could trigger unintended catastrophic damage in certain organs [cite: 23, 31, 63]. 

## Bottom line

The scientific community is pivoting definitively away from the antioxidant paradigm, as decades of clinical data confirm that daily antioxidant supplements fail to extend human lifespan and can actively disrupt the body's natural cellular repair mechanisms. In its place, the targeted demolition strategy of senolytics offers immense promise, fundamentally addressing chronic inflammation by forcing toxic, aged cells into apoptosis. However, while early human clinical trials involving compounds like Dasatinib, Quercetin, and Fisetin prove that we can successfully clear senescent cells from human tissue, these interventions remain highly experimental; their long-term impact on immune function, tissue regeneration, and epigenetic aging requires extensive validation before they can transition from targeted disease treatments into prophylactic anti-aging therapies.

## Sources
1. [Cellular senescence mechanisms](https://pmc.ncbi.nlm.nih.gov/articles/PMC9261318/)
2. [Molecular pathways of aging](https://sciencepg.com/article/10.11648/j.ajbls.20251305.12)
3. [Senescent cells as a therapeutic target](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599677/)
4. [Historical context of cell senescence](https://academic.oup.com/emph/article/12/1/82/7663652)
5. [Molecular mechanisms of growth arrest](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2021.645593/full)
6. [Antioxidants: separating myth from reality](https://www.gowinglife.com/antioxidants-separating-myth-from-reality/)
7. [Vitamins and mortality risk](https://www.sciencedaily.com/releases/2008/04/080415194233.htm)
8. [Dietary supplements and lifespan](https://pmc.ncbi.nlm.nih.gov/articles/PMC3982418/)
9. [The antioxidant myth](https://www.psychologytoday.com/us/blog/diagnosis-diet/201712/the-antioxidant-myth)
10. [Free radical theory of aging](https://pmc.ncbi.nlm.nih.gov/articles/PMC2685276/)
11. [Anti-aging supplements market size](https://www.precedenceresearch.com/anti-aging-supplements-market)
12. [Longevity is becoming mainstream](https://longevity.foundation/tpost/8b0n6obhz1-longevity-is-becoming-mainstream)
13. [Global anti-aging market trends](https://www.snsinsider.com/reports/anti-aging-supplements-market-8498)
14. [Supplement trends 2025](https://www.greenpharm.sk/en/supplement-trends-in-2025/)
15. [Regional anti-aging supplement analysis](https://www.cognitivemarketresearch.com/anti-aging-supplements-market-report)
16. [Systematic review of antioxidant efficacy](https://www.researchgate.net/publication/258128996_The_Free_Radical_Theory_of_Aging_and_Antioxidant_Supplements_A_Systematic_Review)
17. [Free-radical theory of aging](https://en.wikipedia.org/wiki/Free-radical_theory_of_aging)
18. [Oxidative stress and healthy aging](http://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue1,Article262.pdf)
19. [ROS as modulators of physiological processes](https://pmc.ncbi.nlm.nih.gov/articles/PMC3749699/)
20. [Criticisms of the free radical theory](https://pmc.ncbi.nlm.nih.gov/articles/PMC3901353/)
21. [Senolytics vs senomorphics](https://www.mdpi.com/2218-273X/15/6/860)
22. [A new class of drugs for anti-aging therapy](https://www.researchgate.net/publication/396353799_SENOLYTICS_AND_SENOMORPHICS_A_NEW_CLASS_OF_DRUGS_FOR_ANTI-AGING_THERAPY)
23. [Do senolytics exist?](https://pmc.ncbi.nlm.nih.gov/articles/PMC8416555/)
24. [Nutraceuticals and cellular senescence](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2020.00218/full)
25. [Oxidative stress and cell senescence](https://pmc.ncbi.nlm.nih.gov/articles/PMC9311946/)
26. [Senolytic drugs and immune cells](https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2023.1161799/full)
27. [Clinical trials on fisetin](https://www.lifeextension.com/magazine/2021/2/clinical-trials-fisetin-reduce-aging)
28. [Phase 2 trial of dasatinib and quercetin](https://www.fightaging.org/archives/2024/07/results-from-a-phase-2-trial-of-senolytic-therapy-dasatinib-and-quercetin-for-osteoporosis/)
29. [Clinical use guidance for senolytics](https://www.droracle.ai/articles/906051/is-it-appropriate-to-use-senolytic-agents-such-as)
30. [Fisetin research in older adults](https://recellence.com/en/populations-fisetin-older-adults)
31. [Precision geroscience roadmap](https://www.researchgate.net/publication/392689285_Targeting_Senescence_A_Review_of_Senolytics_and_Senomorphics_in_Anti-Aging_Interventions)
32. [Combination therapies for lifespan extension](https://www.aging-us.com/article/206078/text)
33. [Endocrine disorders and senescence](https://academic.oup.com/edrv/article/45/5/655/7631421)
34. [Fisetin vs D+Q comparison](https://www.rapamycin.news/t/grok-comparison-of-fisetin-and-d-q/23339)
35. [Dietary bioactives and senescence](https://www.mdpi.com/1422-0067/27/8/3651)
36. [Longitudinal study on epigenetic clocks](https://www.aging-us.com/news-room/A-Longitudinal-Study-on-Dasatinib-Quercetin-and-Fisetin-Senolytic-Interventions)
37. [Senolytics and DNA methylation](https://pubmed.ncbi.nlm.nih.gov/38393697/)
38. [Impact of DQ and Fisetin on aging](https://pmc.ncbi.nlm.nih.gov/articles/PMC10929829/)
39. [D+Q trial in cognitive impairment](https://www.fightaging.org/archives/2025/03/results-from-a-small-trial-of-dasatinib-and-quercetin-in-patients-with-mild-cognitive-impairment/)
40. [Clinical trial: Senolytics for glioma](https://clinicaltrials.gov/study/NCT07025226)
41. [Time in China](https://www.google.com/search?q=time+in+China)
42. [Time in Japan](https://www.google.com/search?q=time+in+Japan)
43. [Antioxidant interference with exercise](https://pmc.ncbi.nlm.nih.gov/articles/PMC5023714/)
44. [Antioxidants and exercise performance](https://longevity.technology/news/antioxidants-and-exercise-how-they-work-together-to-boost-performance/)
45. [Redox modulation in exercise](https://www.researchgate.net/publication/275101266_Redox_modulation_of_mitochondriogenesis_in_exercise_Doesantioxidantsupplementation_blunt_thebenefits_of_exercise_training)
46. [Redox signaling in skeletal muscle](https://pmc.ncbi.nlm.nih.gov/articles/PMC7284926/)
47. [Mitochondrial adaptation during exercise](https://pmc.ncbi.nlm.nih.gov/articles/PMC8624755/)
48. [Therapeutic strategies targeting senescent cells](https://pmc.ncbi.nlm.nih.gov/articles/PMC11921816/)
49. [Senolytic strategies for chronic disease](https://journal.medtigo.com/senescence-and-beyond-exploring-senolytic-strategies-for-chronic-disease/)
50. [Natural killer cells as senolytics](https://www.globenewswire.com/news-release/2024/04/08/2859230/0/en/celularity-to-present-data-showing-senescent-cell-elimination-by-off-the-shelf-natural-killer-cells-derived-from-human-placental-cells.html)
51. [Future of aging research at Cedars-Sinai](https://www.cedars-sinai.org/stories-and-insights/innovation-and-research/the-future-of-aging-research)
52. [Senolytic supplements market projections](https://www.pharmiweb.com/press-release/2025-08-06/senolytic-supplements-market-to-reach-350-million-by-2025-poised-for-15-cagr-through-2032)
53. [Anti-aging research developments for 2025](https://int.livhospital.com/anti-aging-research-2024-new-for-2025/)
54. [Senolytics and skeletal health in older humans](https://clinicaltrials.gov/study/NCT04313634)
55. [Advances in senotherapeutics and seno-antigens](https://pubmed.ncbi.nlm.nih.gov/39727337/)
56. [China clinical trial volume eclipses Europe](https://www.bioworld.com/articles/726990-china-eclipses-europe-for-clinical-trial-starts-lek-report)
57. [SGLT2 inhibitors and senolysis](https://en.juntendo.ac.jp/highlights/news/nid743)
58. [Development of senolytic vaccines](https://en.juntendo.ac.jp/highlights/news/nid69)
59. [Cell surface proteins in cellular senescence](https://pubmed.ncbi.nlm.nih.gov/39727337/)
60. [Juntendo University research highlights](https://www.juntendo.ac.jp/assets/ResearchHighlight_EN.pdf)
61. [Safety monitoring and dosing for senolytics](https://www.droracle.ai/articles/1050056/what-are-the-recommended-dosing-regimens-safety-monitoring-and)
62. [Hit-and-run dosing protocols](https://foresight.org/resource/clinical-trials-senolytics-dr-james-kirkland-mayo-clinic/)
63. [Therapeutic efficacy of quercetin and fisetin](https://www.mdpi.com/1422-0067/27/8/3651)
64. [Senolytic clinical trial protocols](https://cdn.clinicaltrials.gov/large-docs/11/NCT04771611/Prot_SAP_000.pdf)
65. [Intermittent administration of senolytics](https://pmc.ncbi.nlm.nih.gov/articles/PMC7992369/)
66. [Time in Japan](https://www.google.com/search?q=time+in+Japan)
67. [Time in China](https://www.google.com/search?q=time+in+China)
68. [SToMP-AD trial initial results](https://www.fightaging.org/archives/2023/05/initial-stomp-ad-trial-results-published-not-yet-enough-data-for-firm-conclusions-to-be-drawn/)
69. [Senolytic therapy for Alzheimer's disease](https://www.nmn.com/news/preliminary-findings-from-clinical-trial-confirm-senolytic-therapys-safety-for-alzheimers)
70. [CNS penetrance of dasatinib and quercetin](https://pmc.ncbi.nlm.nih.gov/articles/PMC10168460/)
71. [Vanguard clinical trial of senolytics for AD](https://scholars.uthscsa.edu/en/publications/senolytic-therapy-to-modulate-the-progression-of-alzheimers-disea-2/)
72. [Outcomes from the SToMP-AD trial](https://www.researchgate.net/publication/370242846_Senolytic_therapy_to_modulate_the_progression_of_Alzheimer's_Disease_SToMP-AD_-_Outcomes_from_the_first_clinical_trial_of_senolytic_therapy_for_Alzheimer's_disease)
73. [Regenerative medicine breakthroughs](https://int.livhospital.com/anti-aging-research-2024-new-for-2025/)
74. [ClinicalTrials.gov skeletal health study](https://clinicaltrials.gov/study/NCT04313634)
75. [Phase 3 trial results for Korean pharma](https://en.sedaily.com/news/2026/05/21/korean-pharma-firms-race-toward-phase-3-trial-results-for)
76. [Clinical trials market trends in South Korea](https://www.norstella.com/insight/spotlight-south-korea-innovation-clinical-trials-market-trends-shaping-2025/)
77. [Systemic spread of cellular aging through blood](https://www.news-medical.net/news/20250624/Korean-scientists-uncover-how-aging-spreads-through-the-blood.aspx)
78. [Lineage tracing of senescent cells](https://www.nsfc.gov.cn/english/site_1/news/A2/2024/12-27/385.html)
79. [Cell therapy clinical trials in China](https://pmc.ncbi.nlm.nih.gov/articles/PMC12547621/)
80. [Precision anti-aging interventions](https://www.miragenews.com/precision-anti-aging-targets-harmful-senescent-1674637/)
81. [China's precision anti-aging revolution](https://chinamedaccess.com/chinas-precision-anti-aging-revolution-what-international-patients-need-to-know-in-2026/)
82. [Senescence and frailty in chronic kidney disease](https://clinicaltrial.be/en/details/177637?active_not_recruiting=1&completed=0&enrolling_by_invitation=1&not_yet_recruiting=0&only_eligible=0&only_recruiting=0&per_page=20&recruiting=1)
83. [Mayo Clinic senolytic trial objectives](https://www.mayo.edu/research/clinical-trials/cls-20200698)
84. [Evaluation of senolytic drugs for kidney disease](https://www.clinicaltrialsarena.com/news/mayo-clinic-senolytic-drugs-study/)
85. [Dasatinib and quercetin for CKD study details](https://www.withpower.com/trial/phase-3-kidney-diseases-6-2016-aca65)
86. [First human demonstration of senescent cell removal](https://www.sciencedaily.com/releases/2019/09/190918075729.htm)
87. [Clinical trials of senolytics in Type 2 Diabetes](https://www.mdpi.com/2673-4540/6/6/48)
88. [Stem cell therapies in anti-aging](https://int.livhospital.com/anti-aging-research-2024-new-for-2025/)
89. [Phase 1 trial of senolytics for Alzheimer's](https://lifespan.io/results-of-a-phase-1-trial-of-senolytics-for-alzheimers/)
90. [Longevity anti-senescence therapy market trends](https://www.skyquestt.com/report/longevity-anti-senescence-therapy-market)
91. [Time in United Kingdom](https://www.google.com/search?q=time+in+United+Kingdom)
92. [Time in Germany](https://www.google.com/search?q=time+in+Germany)
93. [MC230715 Pilot Study details](https://clinicaltrials.gov/study/NCT07025226)
94. [Reporting requirements for skeletal health study](https://clinicaltrials.gov/study/NCT04313634)
95. [Protocol for senolytics in mental disorders](https://pubmed.ncbi.nlm.nih.gov/40443429/)
96. [Evidence base and safety for senolytics](https://www.droracle.ai/articles/906051/is-it-appropriate-to-use-senolytic-agents-such-as)
97. [Longitudinal epigenetic studies with senolytics](https://pmc.ncbi.nlm.nih.gov/articles/PMC10929829/)

**Sources:**
1. [gowinglife.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEDXfBDRPkEsCHTQIQT92ZvyqiwXdN62IB7huvTTrsOduJyvaDUwe29_-u4aIIQV7hl0mR-JiF5i6L2eCbfhMzRmagwyTOoMSj0eUK_P0x4bOncuVztX8nSz0bBJXBYDR8x3vi7UUhYx6shPaotcHcn0dqvgui6_eqwzg==)
2. [wikipedia.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE_xXD2P7q0pRHTZXHvbn8jpLbnvGf3LNUnjyIvDWXePUb-C6OCENg2HKwrxprKb9NjCA9wV9_mJ9fn3lG9YMCkv1Xbsf4afHSwTeQo8bTWdtZ0tcvC9dyiJdk0zY4ld-bb43oO1grvmoI_z4jeJ1U=)
3. [impactfactor.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGSWhWlw68LbY1geSjVANfHJk7RXl3UtkvGuh5zxL6Khl4LgPGZG8S4_y5l6erk4PFvsK4f9H0UyISRGgQlRgN7iju36Fb7uPeAVHC_QP635vTgiQ7bQcNdcfrwbU_sVoDvmXGjM464xyjIiVBKKzbl11YN-WsEQEMaN4U=)
4. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHELoKBOZcvX4JoVG0_clQl_Rwss_9JFZBBb6fkCGtlt2psuvnYTvvQDDVp04nFkAQHoOGZU7XE6ZoqD_r7fbrNDNvnOmNvCeI7__3Z9isC7EwgfIREdRJyj5EyJ0s_GFbi1zTGpqA=)
5. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEtu64p8qxLuJZo1Nc8pAA-8f4Pj4hO4USG_3T8kGUzbK-6eipy7NGhBS_n69J77t7y3s5IS2nlmwDrjx5uauev3d3ZtB-I2_IeuSI9tlIY3f3nzXR5JgJG5Yjj837HZeP9QJAvV3h6FYYd6WJTOnsL6cZqG8oZTmSbDg06CDZK2GDK_3_SMVgXekoiZpY6tGJxGZ1zRfbl5bYAPK6mGMIXdjnTJoIfOhuylwjrLEn6DHnLBAjmziMWtw==)
6. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHIhXyogHT5w9U23kNh2NijLq9Qzibw2YWde0uajxwcnQSUrc0MzqH-HRQLsOAa0VqHkDMIajGOsVoV0zmsxTenE9d8MS9i0su-ZNA56dG7InFT-GiSiQRGZOHep0gsctx_lwsk6qk=)
7. [sciencedaily.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFaru9u0LvDNgcD907mc1ydK19_oBnbvHYPFgu020Ue96eygSl-BqgoP7BKJchDmgbbSqZ0fjKB8RKdC3DK2mWWCTuj4QdQsKTJHqdJRbY6Jz-StnfQ3tB2ovhKAMoGMnl7Pb1leQbceCr3cc5_KmdMO9Fu)
8. [precedenceresearch.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFzZxBlwkGJhswecZTJfSyU4_44jDLpw7fMAZXv6ZDSJLp5I62AfiM4WYDEO0wZJ-4AiZeffDWGxIjTLNvu59HL1FpZTEKiiA-E4IMNMv94J4MSHWpRPU4OI9WkzEjOPtgmLzG6CbzLQBLpQjmuiLy26JV6NPQ=)
9. [snsinsider.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEyvTtNO85KLBMeo_gq17WMk83MT8KXMO3kzPuOELjJRXdjxFE83Z8l_hehHWN136QgFHNwfJewa2FoysEtpiVcP5JGq4E-YkZR8uA6fhXNRRPFlj6kkPuikXN6wDguvBQzynxDNngBm839OIKqGlm2k4Brc5KDMaIyZw==)
10. [psychologytoday.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGxdh2aBR25oqwtYK8lMI3s088EpG8o0ss3ubk8tJqvVMiKrdE2nQGUP2udLXPPgckgRodY2ZwHJ5eQ7TG73nF7lHfjtNSoBeGGxBYJsOCxdJDdNT5aEor-YCkmd6Q17nUquZWJ3YgajMpgE1APsdAN1EeQUmt2JaLg0G_MdoR1xMcNXIGuyPU=)
11. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHHpzqbmhgmE5-tTzqHgMtt8KKikoPpdFTCtElxTUw1X5PvI6nD0vT1mvwj5r8r0miW4Vk1zHqpWeEUoePdLWOn8xw8KFClChaDEcGJ6QwioLdjGD3-COtVN4soo26PTesH8bFVXjA=)
12. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFt9xgCADLgO_xPc1mOnTJEM6782WuLRmFXQTZUUQ6b5CcJCEv5RM7pXqz1CH4M4DoRPtRxKBTwgK_taqIi7UpRtWQNgiA_UzStQjIEg28GgiE0aXSm_mtaX899EyIx1P3CXJyxSis=)
13. [longevity.technology](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHSAe1JM31tRafvjCaCjNlX0kQiq_hxQA4nEJZySs2CABs6QSFZn9EfgyiLOxz2ugi6juIdFMBTlqqEQ4oQ9qtNeMwBGm7EvTNDlIkgcMH-Rh3paNEfTbAhwdGt4QIJ64tKoYml6e7fpVeCb5dfhskBekxFGKHw-IYxfJBVjzAS14U99HIjGXyBqYc-6DJ8d0gNXc450U9Ti7YhFfiq)
14. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG6KHk29hvp7WhIroyewxJZ3sHw76IHXJJGEUwC62EDGMN7J0bEA2i5kGzsatzcscVFtvxNQZE3usEzIZBts_hf_Bkrb0m_Z0YazsG4sflvlHJztygBX-VtSUfcyKZUxHSTFchcLnI=)
15. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGMLyeJ1wn9dSUkR-JruOkqnce82-eUJESObr22oppBCNbWNNumx7mIMyd-jxsqrt_IFQeNRdiCjkwrrfquv4uS_VP5mdI_YUMwTKIrRo-HDJ7d4YUrjM0JnOpgbR8j4-zNclfpPtU=)
16. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFE-mk-K8wG0koQ4a97niEd5Ml4GCZKgoEuyEDKQ5rs-1aCEmXWXtzKgx69hkIGjYMpfJu7gPLo_a7RqLB27r58TfEeqinBeHqdSxg3bHs19Jk5Vwm3sXBhTklHbcoWVglFjk5Wt7Ciop7ZaZ-646zVkEMej_1Z5nzLKaN5onaWI0viEfiMrZiJ4_ouv17fqstU_Lhw1BQGFwWWQEqwU_U69Bc3Etf3iRZ9P5R8znLP26CJBaUIASRv5X0EeztmLbUhWsQoYZGwSP5U4KJUr5rZOYvsBAjQSvgkgOwt7-GNeW-d)
17. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG3QFvPfLbbxK9wZjdqEb45OhCUY42BBUp8bBTQkx21pVeotIYwPMldAamG9IdhpL70VGEyYulhfG_kTuwp1IOFQAmb39knpoV929P8W3zfvQtQ8AZupFOHKd-hfaEmek4k68tSi2I=)
18. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQ4tvB-bZ5CF4dUawi2CJiaJ2cFNSG89ojtnqOc53yVFe9BmvwwQwwhCqsRCHOz2KFxb5WagksnfjK70WxumsSgYYOvB2ua3k0dH2HKCWZ_NBqepaS0e_SMLEkxj-__zhrF7AX-Mx5lKPP6FmzsPTqQkk1IvU1WJ8UW3YvETmGSt6qYXkyYLv7iRDVdeEZgOUkqgT1LYU5OVaXl_Azu10y)
19. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJu1rtwT0Ns6zOMXx-38_GL8Mx7_S0X4UYS5jkq8yMzQDhrq1qkzRzbvoXpwKCP3WJaYVMAgl0XWug6Js13qHpsM7hNtZHh-Cg2H81QvJNX5ylf9BTD1JeWmHtV0y45cGLz8LxnzTFSsqVbMj0TYr17eZgl2QlENVoZpJqtKP0dtRWDYyMwv0GX3QRpeskYxRFO1Xqy_v87l5bFPjGFVQ=)
20. [sciencepg.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHDAHV6S6SRAniC_OmA5MmYgHhXNJHZSI2nCBinw4cdbvfYS3GFarJa7s4ysC_OnEN5YaC_vweANk7KC3SKOXpSlHOB4PFfx0p90DJOV6CIoPWl5erYnXPTzuPRY_O5PJwl9dZRgQx1rD9Ryw4SaFE=)
21. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFPGnHU00s0VaGrRs9PBvccUZHfKc-IOJeYpcnG6Ym8oJNgWh1wxvRxXRCoB7gR3XnQ-1RvK0TtiiSHUuxhmePoE-v1etqYvLSBm8bkbZk3RjxY9zoiRfJmdkI3fA==)
22. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBnBpk4-0mTpFmMvHzUhY6kLxRDeRTpFCah7hE3Nlxkb27BqPQNg_40M0yO_woHjzhrbRrM4DZAxQlZB4Uyfdn_yS41KY0gWq4oMIG3AhhSzWreH97D9XeGtJx2m5teLjZPwBkRrc=)
23. [miragenews.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHqv1Y0GWU1LTttmQ5uwe9XB_dQvKdXg6_gk6s6cxaQQR1gzqrcCVT-WQNlTJJ88DbsaV-TtHfLwdkC8oUVkgzgww48Xer_a4dflCcpI_kfmqgc483-ZV9lQha4zThVkqWYfaAOmH2Y3a-e1qOSXTcaw1pOXviemoBb9iUyY5eKCimFHClG18M=)
24. [cedars-sinai.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFCtSGvT355ENUv8ZMupHtgicZu6bjGCUGSUVa1_6a5z7O-gztTLaBh5BokU4cXH66f4UHRAz30Pnei-kh2hhjjBozBcvRwpTR6kKsAtLD2TAADG8xHCex4DiOUbwPiwXQJG03YyC4beQtsSGuxgQNQpQKhDLZssp9VReaxPLKNpPi_hNTV9X4N3_ewMvlAmz4ABj8abZDcD0_F2Q==)
25. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG6slDNjQcESeIlKKfBtGUEytf66VRgSYDmMbkGkSuLPy2HZwocCiGPat2hQwY1vYOu2sOQE6So139f_SgSXodVU4pzTtMRHNSsohTiilNGKN65InxtHqpLMCBTEsxXP3Hveyojk84=)
26. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8bAbvlstSXAhQF9qnkSljuISuYf5nM5marBrVXoWCsWOE_1XWV1X3ZJGJWDQK-q8jtcSOlOHXCVkinpy_d1hhj1XOLegm0U358M1HV4OvC48dN_ai2KRnGW6lRNV2-Bdb7eBDREqV)
27. [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGIcHkpxqwuaLixmpyT3vmBilSdj3OQpukLvlyDvV9Q1OYRXih3FX5J1EmO_-fK8jJAULI0uT8tFUS890xDsWtxi0s3v-1GNzmqap47nGbzFyvl-l03a8inY5eEmlr6DPcEnihSWe3XjwkT)
28. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQERspNgNiLE9LyXfNDclnBHAb62vH79nYLub-YYdmuiQ-lYxJDSSNYxIDrn4107fkEw5gvnrEqVZBvYj4CZawMQF8H4Rmm5sj8UJ9-dTrkye7XsxgB89o9HZFK7deNKwjnuX2JnYKlLCvKr3Ng_m9Pq5jFBuFt30nqH6Upjp5EK1m1Ui-QiIyIseVFGNtwNS3v7tY3O5ewvUQt51S2GTqJrIHI39y6wE1_TnKsF6fft)
29. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFkqdHdoLke0_BiZ1Eu_avRFhVflQqCJzrSjsivaNzrA5R-7rDVpb_AjGpeDp5u0u0Te0-lp3cjMLt7sedwS7a4PsUkgJwnTh-fqwkENg03cijo-2yH6fRWFhNTp8Lr1nsUbNOZnuQ=)
30. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFKoT0VcipxzWLXYnA7hXl84qrXrWgyngtuR37KWHTc0Zl7kbSfN4zwomKhFYa5SeHBpcD9GYMJGMKAarVTXd88KNgbcBBw-krma2GPOyk4ydgoNxaG4YwqefsoKJg-lQURK02udCv37ftpUPWoLLRcMcpRQKdxGG_dR0bxEODhOzX0NAQ6NjgqBTbpojIh)
31. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFuY6Y_NW04DeWCcRwCUXUEqfBC91ELOXEGeSaVdrxFPgy0nRLe9IbSGTcDVhbrBf71tQqZE0eBxzcWNr3_-O34PsJnjFDFTxdFZK_9l5Xw4lVcYTXrDF-kVZwGWE-16-JdByIh2QpYwkhRDrY0iD-NMwpVIVcAAp0LnateuJl5sxIGhN7E_j6ISQ0qW1fD0jYZSjZeVefDih_bFxb4la1jK2DdUv1GnjQmT7p1E7mwXdzrvj_b8XG1GNkhtYo6kNaS)
32. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHmpRZmhBUFuJRAB7SIqKauSfEemSK9dUqt_wfAydWzpJp_v-D00fOFwfo58B2wF9F1tRui6LATAOcPXeQD1QJI0Nb9WPe--gZcuFVByl4qZPnGWLdruQT0N2D8hI3nO1Lo)
33. [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGfJuDvwV_rFvKmPRIdq1dSvesemjujiY3F-8emTQg-tHI9Wa4MQb2y2PbwXQK7TtROF9HFmVg97b9DtrySNnxoIcnqpZ-pZpdkueltRcnBE6eUtkdpW0RJHcTTz1LAw0XPHzafPTO1aEv1zw==)
34. [foresight.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHhBB94g41dPSMdDuJMtbwWp-akqqX9gUTIdF_xAaj3Gkz0GYcUL42pXyI-Qa9Ydla0mJTy3jpoiLs9c5egtAh5nc3U39QF5KtKXqznXgc288Nuk1El8UzyE-t39qs3O0Zh0jRoLsRzBjz1wZ7I_jpLDk3QXAVplyrMd5OYpsAnK1ux43eQbyDSxJv19kU=)
35. [droracle.ai](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE28qssVSkSsHDu56qNz3bINSHicAqgx_p_NL11710CwgeiZNm3488WHWmwS53T9Wt-sIuPwzCOilkUqafjYuALtzAJs_tn5WPkNuCIPPVzRW2LWDklo14KIBTyVUJ_ykXo_GdSim_RBBS_c5onMTeU9C63jwdctAjwjKvPQFUkcOcZK4tcLvJQBRp57NFioW_7ydibeap5_SLYoA8=)
36. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGBtjcsPkSzrJRC1iqfQXAPpdYiE830HcqYVdDpsxYm-zD5AYtoGNE9bA9E1moZy-3WuFYyLWU8fFAERCJ8AA5ZN3n13PI7mGpzwa4yhBpNfpRCJ7bBVb26gjahCpw=)
37. [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFAf1DXPaCTK6l0UtypJRhE7-ruv-steS-ERx0fZ1LrP-MCwN9nS0Yr5yRS6wXmr9k61TpcyLT3XRHxOKQ0o4o3y2Idg6h9alUUxLKx0u6SWlNGCidxZ9IiCA5__saRNm0lUB9iHFuEqRw3dMGzJCEAGgkX4SY8w_Y3CkA-wWs=)
38. [rapamycin.news](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEETz1i3TfmT2pfhnpOkcT1qyk3YodCoIaVYtcRsDRZOU5wLAQshLSiYqh6WaQufV4vTzY1jFXygEEqnYwpk-O2XLok2xD2TI04aZL_5sMeSXLaBkszuDYHdoMolTTdBpnsdevLYnWoJW3IjhLDjcIyu_m-4HeeayV6jg==)
39. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEEO1598QBKDZO2NjA7mQKFUARZSSoWFyLMe8s0Q2O2GA4qabhhu0ElNqB1QlQuQLO9-80QKaydCJA1tNfNjg6FljK1hmaK_CMUiwczuhoTixpJ2tck0ZOqgEPcMvBbWZNnhE-jghajf6nHJ_SJnS2v40Q6wmjc_hv9l4GiF9RIemDEyqR1nbG4)
40. [fightaging.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEFNipj8RUMLfrZH-jJLrUaHeeI2ZwnB2nui-0xUB5HA1bYnISiNWLlGlX1CCvrCN3y50kEkTZMZGnN3LT9LgrUMqJJaVx9eDQX1dFABHJXiGlu9VwYM297VaNo-0it9FM9x682bVLYc4bAt1oKnaB601nEJw0qimqyjD4-XNZtcp6zsTH8JhWt0O9LEuSAo8m3zSIOvGLuG0b58L8dY7Z2P0BekEwB-C9vm5lYgxlMc0GcNSjBT2y_IZzBro0=)
41. [clinicaltrials.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFhpxayBUT2MGLCGlq4BC309bH8lJehoMV9iyWDgda5MvSBe2N7uwh0xxGZ-SrArQVMbL1f5MIs245FDF0L4vv7lG0sL47ksAzbQNlDfU7P-SPz-NASPlxhKJuyer-GB4Y6)
42. [lifeextension.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcRkvh97UC4RdKGdx23B40YI30fZUPwalsXjiux1BbkgfGh_Jy68cLacMDlvQtNRwGBgK-cM4eHrCDFxbYBB1E0mTji2xzXURjYxNS-GtdjhlqOXxpYbRR3c8MQz4uz4qQbfukW6qHq5ZCWu_LFgk77MDtZD1XtzkRANwlG4tB09lytAkPt1U=)
43. [recellence.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGrn39hztaQWpUaMzAUy9ls9NKOvHXSChtsfYoqZ0Eoe7SLBbDYgGSNWST_5IdKQv42cvi2FS_WgPUaG4N9fflRx9E7Z3fcXFP7_gDfQ6QQ26A6TGAcBIKfucAQ4ovWADB9rrVFZHr3axP4CY_umsU=)
44. [livhospital.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHgGQW9fFcR9BBBwH4pK1XN7WDp2yOA4F6ZRe3Rg4DWqtCXLitnL7WnpdTJ4Qrw2MY5XH2KVZxmNrfTx7g9wWYIXjZS5EK43y79Jm04lgTy0o5FzBACk3G7x2e_vh9ViNr2SG-WSPpfk_RAtYWn8BdSWFk3jgXd-w==)
45. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH98B_0K2u0hZsXTBVy1jXj6pPE9xXUGgFJZAeyxDA00Z8690trUyTsK3Wroi7gk7pwoGnbzsTk6Wo8rfaNBOLcmnpNZa1SmG5Zr2H82ljmZPhcW2xOPstkTOA=)
46. [pharmiweb.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEJXJRU_OwEXUzSwrldVADHTxlUuS8CQqZ4dGR4PSrVvr8IdMuisP2Km9cBMlYCwsmYpyWPFaXbD0Bx70AWch0BJ0YheASQ2QUEFm7TkR6uOCdtNHCLytojKOTPOnW2UAKnCL6_RolOqvu0DWwhukTLaZDrlg4HkZ4S8AJLQx0xSGVgKaqCma0gbK1u1OHtsu4yCyzSzqhYqEg_0JNObYzLxADdbCfANl2IjYzzrdP2p6CJyxGnBaQGp_1FvuCevYIgVA==)
47. [medtigo.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEgDSQcLjjWIpvEud6VZV--c9iHcrDmoSfnHvUssBI7fzWG_bABKkl5TPapv1lSrGCSWyoElP67IhG8ehNU1ONcEbNkt89YShJqYcpmQHWIOlc0vmeQaHdwx25jFPGQsiMH1jDbp5b0JTTB1ga1M9CyqyUueFw8h_Yv1rbUh3pX4hik6tGQXkt4UJJrwXf9nqLTFU-nvz2pbEzZ)
48. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFNeJFirD5uDWErRB9cX5gfcSOYmW0-4y_mjYd16QYuVpFiYm6npt-AhnH60jcLWmCgf69dp_JIcuCE-kIdmSC6OEh7G_bf75Ttz6-q8dnUVHttAXl04jpHtgbgXxJjMRRYQUh9o6u_)
49. [clinicaltrialsarena.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFC41iN7VJdVPmEz_dTBzaQKsncnT6MRQhJ3b5k3HxNiHQYwdSl2DTg5ANxAm0bFT07Sl4nkbOY12GPCvZ-NZx8G6Uo11gDZcs3wHayt3SzIIKlqcFslm4lF1xK7yC4mgBUYCDGiNvtbD-1WtovoBq7fjv1JXw5X4QmACfG8AfzIg==)
50. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE_g5oQI3XAUieZVB48TEegcSvL7nzeb8snNOBpdkWs5z32IAA50f2GFF6nuwVw84cIw1R3rTrKZJkswOaeOL6htInM0ExCmoXOFmfnBG9EH9UmQqtN1UPSBeq9qi0vw9fV4fUIHpj_)
51. [uthscsa.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHkJzVaJJTRiuxvbCjSTQXRyagIQ1LAkMymxWeStufR_YKRUh4IrqZFTyJhGpdJmqXooN9T1e0kZWQqdnU_L-cnyk4EPU5-uHVwy7OLpBG2aPFmtvW_5Hoy4gICZ7s-MqJtgiQQJ9FHqzs2J7i0tV8xH3eHugI-aIwvRsFCLv1a1GCG13ons-0nPb1bTA_kJ965UQv3K2pR8XY043DvFlQbQ_dX7EXg)
52. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGtZVSE4eaXZ6XoQpJmmHiGlyiwcHxQBQENnlvbHwFOVNGyPKLNZF9jB6zYLDgnyBHG_XTzVz7Glvirn0tyUKwk4QFep2N4lqAHX_1PIKPRMFOvjHrDGxe9D3dm7ooo8zK3mfzOpEzBah8OhSWVggC7Y-X6lRxtVeOpR-icgTuYvU15SVx1Ms7Zeqr3pXhG4Pd9wZ7j6aRT_fD-6STg9SKjYysfGa4uujap_zAHXRkuyXzyUB0PuKl3a3e3bzJbgQLm5RKS4l0xYwOAAMTRrfXiL-yOmuV8xKJLFVYTbrHzAIF5F5NbZkaKWSbuvYIiAC9-avnsZTHo_vnKQScCYMgt4RQ76XS4Do0bGClZ)
53. [fightaging.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFb4LyqdwgiU8s1LzWPZGGdCwJ2LXStGZHKRCSMdFJK3olMYTPe56y9rh-A3xR1chBsaBX4gTzezjZKtuid4_9hYvV3hIpx_i3s8cksGDG7z04JXsii5e9cefay4sq7mfrkt83jqnESSaEhxirRSo-nllcmxP_NMj5j55N0nAqEnqmRu8AP1jvlhfAy7qSE9pDeNS3QI_jXBO4WmgBX67tyFmIMxqWhW9Osqf7S7xATomDnrEUSoM699Dt9-Hl9ODY=)
54. [lifespan.io](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8r_IQRpFMmTLujYIGJB7_Bh2ubk8z6ctd8rYdwYM6hKsxlsbc4OuInA_bVikwVGzqeH62gmqfxAjXFO3Kme4SejKd5h1iQVy8vixy1oBk_L8EDuBoCSdKpAueEhg1tfQDHjpwHyCRYVEC6njHbzli7cSiS0GD5Hkx9bYJCOxHoJ0=)
55. [nmn.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFaHzzwyUY2JAI93KR7S81XVb6FjbQJbuOlhNhkEh0LHVWn7fDuCnBNoJEeFC5boX-LrPHpUKLgLubLDkd-aFUkKBWvgcHWRvpRssPvWMLKKGXKiXDW7MRaJ3NAosO1J6uvxgmPvOFd0uAhqHXUGCaXFmW5_Voo8sydivNUeaT02UReMcQqIA6N1RnigoMfiKBNEamjndfAD8m6wF0sqMgXy8b1K9sFxA==)
56. [skyquestt.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHXJOj7_7mzww1tAY91SG-UlTkvvRu_VIMmMN9LFpokRBoTDRRtUmxFGwSlLIcgmHn0sZDez24ZabfTddwQL3RwGKRr9XFYl0Vqz7-CfdU9oZIUJ348hd5Wr0tKd4uEVlMbxJ68Bj_EMS8LnQnDszUV3qKD6y9I7M82cpn0tYY=)
57. [aging-us.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFrViOAPSIKBddAC7zV_qWM3JaOhsB0D4Sh6wwGkzNFrfEPpsHHkniuRPhPuoMWlCDxUgYNe1uIk2SJNiisHcQG10wOapBDjNzhBaeUm6sOH2zd20CBj3jSCt7-58cFreuHIPrG7vPqAWxOobNG9Md7NXe-efSDJYDBBQx91OYMmxgrfaIOaglz_D5hkDcynDX9Nhj66QYz1xBVORoIXTB9SUfIhZnBnw==)
58. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQELL1sm8tBSOx2gM09s8lKTvaXpeRk7eMH4RCzIi7z5-mH6dTOwMgBlhQo3-bqs204WtpuF3QQXyh2UYhuZXeGGJ3vbUF0zQkU1VZucp_BTUli-ydijua3CC0hfeEoL)
59. [bioworld.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGQJzqWKVulgiR-ExPdjGmwvHAS6BJqnb-tlfNE2cPsgSgSuGfQGnuK8v2uiGo1Cxtui_F92A3BzgALcuFzDCO8tM4pJouL-oGSiapOE_-yTLqmSAVqE3tqXqZ0YKpon4bx1YOhmyzcSD3Gk9EwvYvPLD72py4IJM5EdFlYvdjrfCOa4YwCyaNhTrk8XpcCuuFqMYxxdyuJBQ==)
60. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHCM0XeWjcWCoBZgJAi8W2wK3kxNnClyQVEu6GgXcHez-VPKAi67nbqkYNNyOJA4rartcO7h-bak2grzE4J1QPM6O0tjBRxWjleivzuVx2tbLbZP5R0Xho79BKUp05x)
61. [juntendo.ac.jp](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIA2zJz1NtwV9YcBzuLstUNW2u6anvfggW8wH4PiV9Ux_Ivi7-2D93WpIrFYhP1coNe_XtFScyH39V7tdu42Ssv5JDZ0GyY_r6k-rN964f9b8sWxnLsX7tfzZdNz5881z2-kDg)
62. [news-medical.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHn179WlSl6qxkl0VWexKf_b0DGi462olnqq8RufUNCWpKhe6E9Z9-oBO6yml4__iigXJvfbW4Hzsx67u2u5LGbtq4tXXPiC46g9cAKOB2cQxlumvgtYp8rP_DU5ExeIPjKz_r-nBWK-o9GB0Iw_szzRwWKYc7GjzCoj9rF-wyFuRCMcQRQ5A_vzmYda2TGY1pyIQa3Gr3aXVbmFrEvKufbGVY=)
63. [nsfc.gov.cn](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHVOkgQ9RLJ6WLgjgohGNZqoAs7a5pwD9yAwgw8pYzFVUcB3pNto01iHU8fAVlIvHI3kjc-sC2cs-OI1KYwxxvn40g5zJjw5_avqZdH1fPZ4trnS2uMUTS2gK2qZBbfGiDojWZ-3x5z-EdSKJqaw0X02Qq95hzVwg==)
64. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGvWmJujL-inpUh_SWn22_3vTmxBoioKMS1k7_oT2-J9Psi1EMFYCNh3l8_xVyFGOXuNA8ekCsM7SoBfo-JE0cNBUAKzNyVYuFMw1hH19ERoBGItlXqTexTSK0GdODL01XNXgWWMkGL)